Item 8.01. Other Events.

On June 25, 2022, Arbutus Biopharma Corporation (the "Company") issued a press release announcing the presentation of new clinical and pre-clinical data from its proprietary compounds at the European Association for the Study of the Liver (EASL) International Liver Congress™ (ILC) and providing an update on its AB-836 clinical development program.

On June 27, 2022, the Company held a conference call and webcast presentation to discuss the new data. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

Exhibit Number       Description

  99.1                 Press release dated June 25, 2022
  99.2                 Presentation dated June 27, 2022
104                  Cover page interactive data file (formatted as inline
                     XBRL).

© Edgar Online, source Glimpses